Loading…

l-kynurenine combined with probenecid and the novel synthetic kynurenic acid derivative attenuate nitroglycerin-induced nNOS in the rat caudal trigeminal nucleus

Systemic administration of the nitric oxide (NO) donor nitroglycerin (NTG) triggers a delayed attack without aura in many migraineurs, but not in healthy volunteers. In rats, 4 h after the systemic administration of NTG (10 mg/kg bw, s.c.), the neurons of the caudal trigeminal nucleus (TNC) are acti...

Full description

Saved in:
Bibliographic Details
Published in:Neuropharmacology 2009-09, Vol.57 (4), p.425-429
Main Authors: Vámos, Enikő, Párdutz, Árpád, Varga, Hedvig, Bohár, Zsuzsanna, Tajti, János, Fülöp, Ferenc, Toldi, József, Vécsei, László
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c404t-5e6c88df0efda27fe122ae6c465887979453148d638d54cc0e9ddec67d3dea93
cites
container_end_page 429
container_issue 4
container_start_page 425
container_title Neuropharmacology
container_volume 57
creator Vámos, Enikő
Párdutz, Árpád
Varga, Hedvig
Bohár, Zsuzsanna
Tajti, János
Fülöp, Ferenc
Toldi, József
Vécsei, László
description Systemic administration of the nitric oxide (NO) donor nitroglycerin (NTG) triggers a delayed attack without aura in many migraineurs, but not in healthy volunteers. In rats, 4 h after the systemic administration of NTG (10 mg/kg bw, s.c.), the neurons of the caudal trigeminal nucleus (TNC) are activated and the expression of neuronal NO synthase (nNOS) in the same area is increased suggesting a self-amplifying process in the trigeminal system, which seems to be crucial in migraine pathogenesis. Kynurenic acid (KYNA) and its analogues may exert modulatory effects in many neuropathological conditions, probably via N-methyl- d-aspartate (NMDA) antagonism. Since NMDA receptors play a crucial role in trigeminal pain processing, the aim of our experiments was to compare the effects of l-kynurenine ( l-KYN) combined with probenecid (PROB) or with 2-(2- N, N-dimethylaminoethylamine-1-carbonyl)-1 H-quinolin-4-one hydrochloride alone, a newly synthetized KYNA derivative, on the NTG-induced nNOS expression in the rat TNC. Pretreatment with l-KYN (300 mg/kg bw, i.p.) together with PROB (200 mg/kg bw, i.p.) and KYNA derivative (300 mg/kg bw, i.p.) attenuated the NTG-induced nNOS expression in the rat TNC. Our data suggest that the stimulating effect of NTG, and thus of NO, on the expression of nNOS might be modulated by increasing the KYNA level in the brain, probably through the NMDA receptors. These data could help promote a better understanding of the pathogenesis of headaches and the action of antimigraine drugs.
doi_str_mv 10.1016/j.neuropharm.2009.06.033
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_21114569</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S002839080900197X</els_id><sourcerecordid>21114569</sourcerecordid><originalsourceid>FETCH-LOGICAL-c404t-5e6c88df0efda27fe122ae6c465887979453148d638d54cc0e9ddec67d3dea93</originalsourceid><addsrcrecordid>eNqFkc9u1DAQxi0EokvpKyCfuCWME8dxjlBBi1TRA71bXnvS9ZI4i_9stY_Dm-LtLuqR09jj75tP4x8hlEHNgIlP29pjDstuo8NcNwBDDaKGtn1FVkz2bdWD4K_JCqCRVTuAvCDvYtwCAJdMviUXbOgkSDasyJ-p-nXwOaB3HqlZ5nWplj65tKG7sKzRo3GWam9p2iD1yx4nGg--XJIz9J_XUH2UWQxur5PbI9Upoc86FY9LYXmcDqY8-sp5m01J8D_uf1Lnn6cGnajR2eqJpuAecXa-HH02E-b4nrwZ9RTx6lwvycO3rw_Xt9Xd_c336893leHAU9WhMFLaEXC0uulHZE2jS4-LTsp-6AfetYxLK1ppO24M4GAtGtHb1qIe2kvy8TS2bP07Y0xqdtHgNGmPS46qYYzxThyF8iQ0YYkx4Kh2wc06HBQDdaSjtuqFjjrSUSBUoVOsH84ZeT2jfTGecRTBl5MAy6J7h0FF49CX_3IBTVJ2cf9P-Qv8hKvx</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>21114569</pqid></control><display><type>article</type><title>l-kynurenine combined with probenecid and the novel synthetic kynurenic acid derivative attenuate nitroglycerin-induced nNOS in the rat caudal trigeminal nucleus</title><source>Elsevier</source><creator>Vámos, Enikő ; Párdutz, Árpád ; Varga, Hedvig ; Bohár, Zsuzsanna ; Tajti, János ; Fülöp, Ferenc ; Toldi, József ; Vécsei, László</creator><creatorcontrib>Vámos, Enikő ; Párdutz, Árpád ; Varga, Hedvig ; Bohár, Zsuzsanna ; Tajti, János ; Fülöp, Ferenc ; Toldi, József ; Vécsei, László</creatorcontrib><description>Systemic administration of the nitric oxide (NO) donor nitroglycerin (NTG) triggers a delayed attack without aura in many migraineurs, but not in healthy volunteers. In rats, 4 h after the systemic administration of NTG (10 mg/kg bw, s.c.), the neurons of the caudal trigeminal nucleus (TNC) are activated and the expression of neuronal NO synthase (nNOS) in the same area is increased suggesting a self-amplifying process in the trigeminal system, which seems to be crucial in migraine pathogenesis. Kynurenic acid (KYNA) and its analogues may exert modulatory effects in many neuropathological conditions, probably via N-methyl- d-aspartate (NMDA) antagonism. Since NMDA receptors play a crucial role in trigeminal pain processing, the aim of our experiments was to compare the effects of l-kynurenine ( l-KYN) combined with probenecid (PROB) or with 2-(2- N, N-dimethylaminoethylamine-1-carbonyl)-1 H-quinolin-4-one hydrochloride alone, a newly synthetized KYNA derivative, on the NTG-induced nNOS expression in the rat TNC. Pretreatment with l-KYN (300 mg/kg bw, i.p.) together with PROB (200 mg/kg bw, i.p.) and KYNA derivative (300 mg/kg bw, i.p.) attenuated the NTG-induced nNOS expression in the rat TNC. Our data suggest that the stimulating effect of NTG, and thus of NO, on the expression of nNOS might be modulated by increasing the KYNA level in the brain, probably through the NMDA receptors. These data could help promote a better understanding of the pathogenesis of headaches and the action of antimigraine drugs.</description><identifier>ISSN: 0028-3908</identifier><identifier>EISSN: 1873-7064</identifier><identifier>DOI: 10.1016/j.neuropharm.2009.06.033</identifier><identifier>PMID: 19580819</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject><![CDATA[2-(2- N, N-dimethylaminoethylamine-1-carbonyl)-1 H-quinolin-4-one hydrochloride ; Animals ; Caudal spinal trigeminal nucleus ; Central Nervous System Agents - administration & dosage ; Central Nervous System Agents - pharmacology ; Cervical Vertebrae ; Drug Synergism ; Kynurenic acid ; Kynurenic Acid - analogs & derivatives ; Kynurenic Acid - metabolism ; Kynurenine - administration & dosage ; Kynurenine - pharmacology ; Male ; Neuronal nitric oxide synthase ; Nitric Oxide Donors - administration & dosage ; Nitric Oxide Donors - pharmacology ; Nitric Oxide Synthase Type I - metabolism ; Nitroglycerin ; Nitroglycerin - administration & dosage ; Nitroglycerin - pharmacology ; Probenecid - administration & dosage ; Probenecid - pharmacology ; Quinolones - administration & dosage ; Quinolones - chemistry ; Quinolones - pharmacology ; Rat ; Rats ; Rats, Sprague-Dawley ; Spinal Cord - drug effects ; Spinal Cord - enzymology ; Spinal Cord - metabolism ; Time Factors ; Trigeminal Nuclei - drug effects ; Trigeminal Nuclei - enzymology ; Trigeminal Nuclei - metabolism]]></subject><ispartof>Neuropharmacology, 2009-09, Vol.57 (4), p.425-429</ispartof><rights>2009 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c404t-5e6c88df0efda27fe122ae6c465887979453148d638d54cc0e9ddec67d3dea93</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19580819$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vámos, Enikő</creatorcontrib><creatorcontrib>Párdutz, Árpád</creatorcontrib><creatorcontrib>Varga, Hedvig</creatorcontrib><creatorcontrib>Bohár, Zsuzsanna</creatorcontrib><creatorcontrib>Tajti, János</creatorcontrib><creatorcontrib>Fülöp, Ferenc</creatorcontrib><creatorcontrib>Toldi, József</creatorcontrib><creatorcontrib>Vécsei, László</creatorcontrib><title>l-kynurenine combined with probenecid and the novel synthetic kynurenic acid derivative attenuate nitroglycerin-induced nNOS in the rat caudal trigeminal nucleus</title><title>Neuropharmacology</title><addtitle>Neuropharmacology</addtitle><description>Systemic administration of the nitric oxide (NO) donor nitroglycerin (NTG) triggers a delayed attack without aura in many migraineurs, but not in healthy volunteers. In rats, 4 h after the systemic administration of NTG (10 mg/kg bw, s.c.), the neurons of the caudal trigeminal nucleus (TNC) are activated and the expression of neuronal NO synthase (nNOS) in the same area is increased suggesting a self-amplifying process in the trigeminal system, which seems to be crucial in migraine pathogenesis. Kynurenic acid (KYNA) and its analogues may exert modulatory effects in many neuropathological conditions, probably via N-methyl- d-aspartate (NMDA) antagonism. Since NMDA receptors play a crucial role in trigeminal pain processing, the aim of our experiments was to compare the effects of l-kynurenine ( l-KYN) combined with probenecid (PROB) or with 2-(2- N, N-dimethylaminoethylamine-1-carbonyl)-1 H-quinolin-4-one hydrochloride alone, a newly synthetized KYNA derivative, on the NTG-induced nNOS expression in the rat TNC. Pretreatment with l-KYN (300 mg/kg bw, i.p.) together with PROB (200 mg/kg bw, i.p.) and KYNA derivative (300 mg/kg bw, i.p.) attenuated the NTG-induced nNOS expression in the rat TNC. Our data suggest that the stimulating effect of NTG, and thus of NO, on the expression of nNOS might be modulated by increasing the KYNA level in the brain, probably through the NMDA receptors. These data could help promote a better understanding of the pathogenesis of headaches and the action of antimigraine drugs.</description><subject>2-(2- N, N-dimethylaminoethylamine-1-carbonyl)-1 H-quinolin-4-one hydrochloride</subject><subject>Animals</subject><subject>Caudal spinal trigeminal nucleus</subject><subject>Central Nervous System Agents - administration &amp; dosage</subject><subject>Central Nervous System Agents - pharmacology</subject><subject>Cervical Vertebrae</subject><subject>Drug Synergism</subject><subject>Kynurenic acid</subject><subject>Kynurenic Acid - analogs &amp; derivatives</subject><subject>Kynurenic Acid - metabolism</subject><subject>Kynurenine - administration &amp; dosage</subject><subject>Kynurenine - pharmacology</subject><subject>Male</subject><subject>Neuronal nitric oxide synthase</subject><subject>Nitric Oxide Donors - administration &amp; dosage</subject><subject>Nitric Oxide Donors - pharmacology</subject><subject>Nitric Oxide Synthase Type I - metabolism</subject><subject>Nitroglycerin</subject><subject>Nitroglycerin - administration &amp; dosage</subject><subject>Nitroglycerin - pharmacology</subject><subject>Probenecid - administration &amp; dosage</subject><subject>Probenecid - pharmacology</subject><subject>Quinolones - administration &amp; dosage</subject><subject>Quinolones - chemistry</subject><subject>Quinolones - pharmacology</subject><subject>Rat</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Spinal Cord - drug effects</subject><subject>Spinal Cord - enzymology</subject><subject>Spinal Cord - metabolism</subject><subject>Time Factors</subject><subject>Trigeminal Nuclei - drug effects</subject><subject>Trigeminal Nuclei - enzymology</subject><subject>Trigeminal Nuclei - metabolism</subject><issn>0028-3908</issn><issn>1873-7064</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNqFkc9u1DAQxi0EokvpKyCfuCWME8dxjlBBi1TRA71bXnvS9ZI4i_9stY_Dm-LtLuqR09jj75tP4x8hlEHNgIlP29pjDstuo8NcNwBDDaKGtn1FVkz2bdWD4K_JCqCRVTuAvCDvYtwCAJdMviUXbOgkSDasyJ-p-nXwOaB3HqlZ5nWplj65tKG7sKzRo3GWam9p2iD1yx4nGg--XJIz9J_XUH2UWQxur5PbI9Upoc86FY9LYXmcDqY8-sp5m01J8D_uf1Lnn6cGnajR2eqJpuAecXa-HH02E-b4nrwZ9RTx6lwvycO3rw_Xt9Xd_c336893leHAU9WhMFLaEXC0uulHZE2jS4-LTsp-6AfetYxLK1ppO24M4GAtGtHb1qIe2kvy8TS2bP07Y0xqdtHgNGmPS46qYYzxThyF8iQ0YYkx4Kh2wc06HBQDdaSjtuqFjjrSUSBUoVOsH84ZeT2jfTGecRTBl5MAy6J7h0FF49CX_3IBTVJ2cf9P-Qv8hKvx</recordid><startdate>20090901</startdate><enddate>20090901</enddate><creator>Vámos, Enikő</creator><creator>Párdutz, Árpád</creator><creator>Varga, Hedvig</creator><creator>Bohár, Zsuzsanna</creator><creator>Tajti, János</creator><creator>Fülöp, Ferenc</creator><creator>Toldi, József</creator><creator>Vécsei, László</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope></search><sort><creationdate>20090901</creationdate><title>l-kynurenine combined with probenecid and the novel synthetic kynurenic acid derivative attenuate nitroglycerin-induced nNOS in the rat caudal trigeminal nucleus</title><author>Vámos, Enikő ; Párdutz, Árpád ; Varga, Hedvig ; Bohár, Zsuzsanna ; Tajti, János ; Fülöp, Ferenc ; Toldi, József ; Vécsei, László</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c404t-5e6c88df0efda27fe122ae6c465887979453148d638d54cc0e9ddec67d3dea93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>2-(2- N, N-dimethylaminoethylamine-1-carbonyl)-1 H-quinolin-4-one hydrochloride</topic><topic>Animals</topic><topic>Caudal spinal trigeminal nucleus</topic><topic>Central Nervous System Agents - administration &amp; dosage</topic><topic>Central Nervous System Agents - pharmacology</topic><topic>Cervical Vertebrae</topic><topic>Drug Synergism</topic><topic>Kynurenic acid</topic><topic>Kynurenic Acid - analogs &amp; derivatives</topic><topic>Kynurenic Acid - metabolism</topic><topic>Kynurenine - administration &amp; dosage</topic><topic>Kynurenine - pharmacology</topic><topic>Male</topic><topic>Neuronal nitric oxide synthase</topic><topic>Nitric Oxide Donors - administration &amp; dosage</topic><topic>Nitric Oxide Donors - pharmacology</topic><topic>Nitric Oxide Synthase Type I - metabolism</topic><topic>Nitroglycerin</topic><topic>Nitroglycerin - administration &amp; dosage</topic><topic>Nitroglycerin - pharmacology</topic><topic>Probenecid - administration &amp; dosage</topic><topic>Probenecid - pharmacology</topic><topic>Quinolones - administration &amp; dosage</topic><topic>Quinolones - chemistry</topic><topic>Quinolones - pharmacology</topic><topic>Rat</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Spinal Cord - drug effects</topic><topic>Spinal Cord - enzymology</topic><topic>Spinal Cord - metabolism</topic><topic>Time Factors</topic><topic>Trigeminal Nuclei - drug effects</topic><topic>Trigeminal Nuclei - enzymology</topic><topic>Trigeminal Nuclei - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vámos, Enikő</creatorcontrib><creatorcontrib>Párdutz, Árpád</creatorcontrib><creatorcontrib>Varga, Hedvig</creatorcontrib><creatorcontrib>Bohár, Zsuzsanna</creatorcontrib><creatorcontrib>Tajti, János</creatorcontrib><creatorcontrib>Fülöp, Ferenc</creatorcontrib><creatorcontrib>Toldi, József</creatorcontrib><creatorcontrib>Vécsei, László</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><jtitle>Neuropharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vámos, Enikő</au><au>Párdutz, Árpád</au><au>Varga, Hedvig</au><au>Bohár, Zsuzsanna</au><au>Tajti, János</au><au>Fülöp, Ferenc</au><au>Toldi, József</au><au>Vécsei, László</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>l-kynurenine combined with probenecid and the novel synthetic kynurenic acid derivative attenuate nitroglycerin-induced nNOS in the rat caudal trigeminal nucleus</atitle><jtitle>Neuropharmacology</jtitle><addtitle>Neuropharmacology</addtitle><date>2009-09-01</date><risdate>2009</risdate><volume>57</volume><issue>4</issue><spage>425</spage><epage>429</epage><pages>425-429</pages><issn>0028-3908</issn><eissn>1873-7064</eissn><abstract>Systemic administration of the nitric oxide (NO) donor nitroglycerin (NTG) triggers a delayed attack without aura in many migraineurs, but not in healthy volunteers. In rats, 4 h after the systemic administration of NTG (10 mg/kg bw, s.c.), the neurons of the caudal trigeminal nucleus (TNC) are activated and the expression of neuronal NO synthase (nNOS) in the same area is increased suggesting a self-amplifying process in the trigeminal system, which seems to be crucial in migraine pathogenesis. Kynurenic acid (KYNA) and its analogues may exert modulatory effects in many neuropathological conditions, probably via N-methyl- d-aspartate (NMDA) antagonism. Since NMDA receptors play a crucial role in trigeminal pain processing, the aim of our experiments was to compare the effects of l-kynurenine ( l-KYN) combined with probenecid (PROB) or with 2-(2- N, N-dimethylaminoethylamine-1-carbonyl)-1 H-quinolin-4-one hydrochloride alone, a newly synthetized KYNA derivative, on the NTG-induced nNOS expression in the rat TNC. Pretreatment with l-KYN (300 mg/kg bw, i.p.) together with PROB (200 mg/kg bw, i.p.) and KYNA derivative (300 mg/kg bw, i.p.) attenuated the NTG-induced nNOS expression in the rat TNC. Our data suggest that the stimulating effect of NTG, and thus of NO, on the expression of nNOS might be modulated by increasing the KYNA level in the brain, probably through the NMDA receptors. These data could help promote a better understanding of the pathogenesis of headaches and the action of antimigraine drugs.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>19580819</pmid><doi>10.1016/j.neuropharm.2009.06.033</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0028-3908
ispartof Neuropharmacology, 2009-09, Vol.57 (4), p.425-429
issn 0028-3908
1873-7064
language eng
recordid cdi_proquest_miscellaneous_21114569
source Elsevier
subjects 2-(2- N, N-dimethylaminoethylamine-1-carbonyl)-1 H-quinolin-4-one hydrochloride
Animals
Caudal spinal trigeminal nucleus
Central Nervous System Agents - administration & dosage
Central Nervous System Agents - pharmacology
Cervical Vertebrae
Drug Synergism
Kynurenic acid
Kynurenic Acid - analogs & derivatives
Kynurenic Acid - metabolism
Kynurenine - administration & dosage
Kynurenine - pharmacology
Male
Neuronal nitric oxide synthase
Nitric Oxide Donors - administration & dosage
Nitric Oxide Donors - pharmacology
Nitric Oxide Synthase Type I - metabolism
Nitroglycerin
Nitroglycerin - administration & dosage
Nitroglycerin - pharmacology
Probenecid - administration & dosage
Probenecid - pharmacology
Quinolones - administration & dosage
Quinolones - chemistry
Quinolones - pharmacology
Rat
Rats
Rats, Sprague-Dawley
Spinal Cord - drug effects
Spinal Cord - enzymology
Spinal Cord - metabolism
Time Factors
Trigeminal Nuclei - drug effects
Trigeminal Nuclei - enzymology
Trigeminal Nuclei - metabolism
title l-kynurenine combined with probenecid and the novel synthetic kynurenic acid derivative attenuate nitroglycerin-induced nNOS in the rat caudal trigeminal nucleus
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T13%3A23%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=l-kynurenine%20combined%20with%20probenecid%20and%20the%20novel%20synthetic%20kynurenic%20acid%20derivative%20attenuate%20nitroglycerin-induced%20nNOS%20in%20the%20rat%20caudal%20trigeminal%20nucleus&rft.jtitle=Neuropharmacology&rft.au=V%C3%A1mos,%20Enik%C5%91&rft.date=2009-09-01&rft.volume=57&rft.issue=4&rft.spage=425&rft.epage=429&rft.pages=425-429&rft.issn=0028-3908&rft.eissn=1873-7064&rft_id=info:doi/10.1016/j.neuropharm.2009.06.033&rft_dat=%3Cproquest_cross%3E21114569%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c404t-5e6c88df0efda27fe122ae6c465887979453148d638d54cc0e9ddec67d3dea93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=21114569&rft_id=info:pmid/19580819&rfr_iscdi=true